Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0HCQQE)
| ADC Name |
XNW28012
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
XNW28012; XNW28; YL204
Click to Show/Hide
|
|||||
| Organization |
XNW Pharma (Sinovent) (Originator);MediLink Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-tissue factor antibody
|
Antibody Info | ||||
| Antigen Name |
Tissue factor (F3)
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
VK*G-NHCH2-O linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
pelitecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Colorectal cancer | ||||
| Pancreatic cancer | ||||
| Ovarian cancer | ||||
| Cervical cancer | ||||
| Unspecific solid tumor |